- $1.79bn
- $1.74bn
- $1.80m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 154.65 | ||
| Price to Tang. Book | 154.65 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1,003.37 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -115.03% | ||
| Return on Equity | -2031.05% | ||
| Operating Margin | -13980.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 13.21 | 12.89 | 7.23 | 2.19 | 1.8 | n/a | 2 | -26.85% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2.
Directors
- Mark Lappe CHM (48)
- Brendan Eckelman CFD (42)
- Kelly Deck CFO (41)
- David Matly OTH
- Klaus Wagner OTH (49)
- Douglas Forsyth IND (52)
- Jon Kayyem IND (57)
- Kimberly Manhard IND (61)
- Kristiina Vuori IND (53)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 17th, 2017
- Public Since
- August 19th, 2020
- No. of Shareholders
- 14
- No. of Employees
- 166
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 52,401,941
- Address
- 11025 N. Torrey Pines Road, Suite 200, LA JOLLA, 92037
- Web
- https://inhibrx.com/
- Phone
- +1 8587954220
- Auditors
- BDO USA, P.C.
Upcoming Events for INBX
Q3 2024 Inhibrx Inc Earnings Release
Similar to INBX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Inhibrx share price?
As of Today at 21:19 UTC, shares in Inhibrx are trading at $34.14. This share price information is delayed by 15 minutes.
How has the Inhibrx share price performed this year?
Shares in Inhibrx last closed at $34.14 and the price had moved by +48.24% over the past 365 days. In terms of relative price strength the Inhibrx share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Inhibrx?
The overall consensus recommendation for Inhibrx is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Inhibrx dividend yield?
Inhibrx does not currently pay a dividend.
Does Inhibrx pay a dividend?
Inhibrx does not currently pay a dividend.
When does Inhibrx next pay dividends?
Inhibrx does not currently pay a dividend.
How do I buy Inhibrx shares?
To buy shares in Inhibrx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inhibrx?
As of the previous close price of $34.14, shares in Inhibrx had a market capitalisation of $1.79bn.
Where are Inhibrx shares listed?
Here are the trading details for Inhibrx:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: INBX
What kind of share is Inhibrx?
Based on an overall assessment of its quality, value and momentum Inhibrx is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inhibrx share price forecast for 2024?
The analyst consensus target price for shares in Inhibrx is $35.50. That is 3.98% above the last closing price of $34.14.
Analysts covering Inhibrx currently have a consensus Earnings Per Share (EPS) forecast of -$5.87 for the next financial year.
Find out moreWhat is the trend in the Inhibrx share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inhibrx. Over the past six months, its share price has outperformed the S&P500 Index by +36.52%.
As of the last closing price of $34.14, shares in Inhibrx were trading +20.79% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inhibrx PE Ratio?
The Inhibrx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $34.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inhibrx?
Inhibrx's management team is headed by:
- Mark Lappe - CHM
- Brendan Eckelman - CFD
- Kelly Deck - CFO
- David Matly - OTH
- Klaus Wagner - OTH
- Douglas Forsyth - IND
- Jon Kayyem - IND
- Kimberly Manhard - IND
- Kristiina Vuori - IND